Monopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson Disease

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/6/2026

1. LULU
2. ZS
3. IOT
4. SPY
5. PATH
6. DOCU
7. ASAN
8. NVDA
9. CIEN
10. GWRE

Go back to Monopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson Disease
(NASDAQ: MNPR) Delayed: 117.56 -0.99 (0.84%)
Previous Close $118.55    52 Week High $ 
Open $117.85    52 Week Low $ 
Day High $119.00    P/E N/A 
Day Low $116.21    EPS $ 
Volume 82,204